SNX29-CIITA Fusion FISH Probe
The SNX29-CIITA Fusion FISH Probe is used to confirm a fusion of the SNX29 and CIITA genes. The fusion of the SNX29 and CIITA genes has been associated with Cervical Squamous Cell Carcinoma And Endocervical Adenocarcinoma. These probes are FISH confirmed on normal peripheral blood in both interphase nuclei and metaphase spreads before shipment. Typical turnaround time for this product is 7-14 days after purchase.
** This product is for in vitro and research use only. This product is not intended for diagnostic use. Please note that both genes fall on the same chromosome and inter-chromosomal detection may be difficult to detect depending on the genes proximity to one another. Please consult our support staff before ordering this product to ensure that the probe can be designed to meet your specific needs.
| SKU | Test Kits | Buffer | Dye Color | Order Now |
|---|---|---|---|---|
| SNX29-CIITA-20-ORGR (Standard Design) | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-RERE | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-REOR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-REGO | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-REGR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-REAQ | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-ORRE | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-OROR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-ORGO | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-ORAQ | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GORE | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GOOR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GOGO | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GOGR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GOAQ | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GRRE | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GROR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GRGO | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GRGR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-GRAQ | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-AQRE | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-AQOR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-AQGO | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-AQGR | 20 (40 μL) | 200 μL |
|
|
| SNX29-CIITA-20-AQAQ | 20 (40 μL) | 200 μL |
|
CIITA Gene Summary
This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the "master control factor" for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Nov 2013]
Gene Name: Class II Major Histocompatibility Complex Transactivator
Chromosome: CHR16: 10971054 -11018840
Locus: 16p13.13
SNX29 Gene Summary
The Sorting Nexin 29 (SNX29) gene is located on chr16 :12070601-12668146 at 16p13.13-p13.12.
Gene Name: Sorting Nexin 29
Chromosome: CHR16: 12070601 -12668146
Locus: 16p13.13-p13.12
Gene Diseases
The SNX29 CIITA Fusion has been associated with the following diseases:
| Disease Name |
|---|
| Cervical Squamous Cell Carcinoma And Endocervical Adenocarcinoma |
FISH Probe Protocols
| Protocol, Procedure, or Form Name | Last Modified | Download |
|---|